Trials / Completed
CompletedNCT00601770
Virological Response Study of the HCV Vaccine IC41
Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Valneva Austria GmbH · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41. Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IC41 | injection |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-01-28
- Last updated
- 2014-02-11
Locations
8 sites across 3 countries: Germany, Poland, Romania
Source: ClinicalTrials.gov record NCT00601770. Inclusion in this directory is not an endorsement.